Merck, Eisai enter into $5.76bn oncology alliance

This article was originally published here

Merck has formed an oncology collaboration with Eisai to jointly develop and commercialize the latter’s Lenvima cancer treatment both as a monotherapy as well as in combination with its anti-PD-1 therapy, Keytruda, for various types of cancer.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply